SI3464361T1 - Protitelesa proti CD40 in njihove uporabe - Google Patents

Protitelesa proti CD40 in njihove uporabe

Info

Publication number: SI3464361T1
Authority: SI; Slovenia
Prior art keywords: antibodies
Prior art date: 2016-05-27

Application number

SI201731001T

Other languages

English (en)

Inventor

Diane Hollenbaugh

Shiming Ye

Diane Sau Mun COHEN

Original Assignee

Abbvie Biotherapeutics Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-27

Filing date

2017-05-26

Publication date

2022-01-31

2017-05-26 Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.

2022-01-31 Publication of SI3464361T1 publication Critical patent/SI3464361T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SI201731001T 2016-05-27 2017-05-26 Protitelesa proti CD40 in njihove uporabe SI3464361T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662342417P	2016-05-27	2016-05-27
EP17728411.4A EP3464361B1 (en)	2016-05-27	2017-05-26	Anti-cd40 antibodies and their uses
PCT/US2017/034681 WO2017205742A1 (en)	2016-05-27	2017-05-26	Anti-cd40 antibodies and their uses

Publications (1)

Publication Number	Publication Date
SI3464361T1 true SI3464361T1 (sl)	2022-01-31

Family

ID=59014833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201731001T SI3464361T1 (sl)	2016-05-27	2017-05-26	Protitelesa proti CD40 in njihove uporabe

Country Status (35)

Country	Link
US (8)	US10519243B2 (sl)
EP (2)	EP3464361B1 (sl)
JP (2)	JP2019523221A (sl)
KR (2)	KR102366355B1 (sl)
CN (1)	CN109476750B (sl)
AR (2)	AR108611A1 (sl)
AU (1)	AU2017271602A1 (sl)
BR (1)	BR112018074468A2 (sl)
CA (1)	CA3025347A1 (sl)
CL (1)	CL2018003366A1 (sl)
CO (1)	CO2018012699A2 (sl)
CR (1)	CR20180605A (sl)
CY (1)	CY1124806T1 (sl)
DO (1)	DOP2018000258A (sl)
EC (1)	ECSP18094829A (sl)
ES (1)	ES2901722T3 (sl)
HR (1)	HRP20211882T1 (sl)
HU (1)	HUE056670T2 (sl)
IL (1)	IL263223B2 (sl)
LT (1)	LT3464361T (sl)
MX (1)	MX393455B (sl)
MY (1)	MY195442A (sl)
NZ (1)	NZ748644A (sl)
PE (1)	PE20190970A1 (sl)
PH (1)	PH12018502456A1 (sl)
PL (1)	PL3464361T3 (sl)
PT (1)	PT3464361T (sl)
RS (1)	RS62726B1 (sl)
RU (1)	RU2752049C2 (sl)
SG (2)	SG11201810522UA (sl)
SI (1)	SI3464361T1 (sl)
SM (1)	SMT202100721T1 (sl)
TW (2)	TWI761348B (sl)
UA (1)	UA123111C2 (sl)
WO (1)	WO2017205742A1 (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2214701B1 (en) *	2007-11-01	2016-08-03	The Board of Trustees of the University of Arkansas	Compositions and methods of enhancing immune responses to eimeria
SI3464361T1 (sl) *	2016-05-27	2022-01-31	Abbvie Biotherapeutics Inc.	Protitelesa proti CD40 in njihove uporabe
CA3097007A1 (en) *	2018-04-20	2019-10-24	Lyvgen Biopharma Co., Ltd.	Anti-cd40 antibodies and uses thereof
JP7515475B2 (ja)	2018-11-23	2024-07-12	ストライクファーマアクティエボラーグ	二重特異性コンジュゲート
TW202039558A (zh) *	2018-11-30	2020-11-01	大陸商江蘇恆瑞醫藥股份有限公司	抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
CN111454364B (zh) *	2019-03-04	2021-03-02	北京天广实生物技术股份有限公司	结合cd40的抗体及其用途
US10570210B1 (en) *	2019-03-04	2020-02-25	Beijing Mabworks Biotech Co.Ltd	Antibodies binding CD40 and uses thereof
EP3947454A1 (en)	2019-03-27	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Recombinant proteins with cd40 activating properties
WO2020207470A1 (zh) *	2019-04-10	2020-10-15	南开大学	抗cd40抗体及其用途
GB201910900D0 (en) *	2019-07-31	2019-09-11	Scancell Ltd	Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
US20220370418A1 (en)	2019-09-09	2022-11-24	Basilea Pharmaceutica International AG	Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CA3148890A1 (en) *	2019-09-11	2021-03-18	Novartis Ag	A method for preventing human virus associated disorders in patients
JP2022553108A (ja) *	2019-10-23	2022-12-21	リビジェンバイオファーマホールディングスリミテッド	抗ｃｄ４０結合分子およびそのようなものを含む二重特異性抗体
CA3157516A1 (en) *	2019-11-08	2021-05-14	Xinyan Zhao	Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
CA3163358A1 (en) *	2019-12-03	2021-06-10	Evotec International Gmbh	Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en) *	2020-05-28	2020-07-15	Quine Medical Ab	Anti-CD40 antibody
WO2022020109A1 (en) *	2020-07-23	2022-01-27	Dyne Therapeutics, Inc.	Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN115403670A (zh) *	2021-05-26	2022-11-29	安徽瀚海博兴生物技术有限公司	抗cd40抗体及其用途
CA3257929A1 (en) *	2022-05-31	2025-04-22	Futuregen Biopharmaceutical (Beijing) Co., Ltd.	Anti-CD40 antibodies, bispecific anti-PD-L1×CD40 antibodies, and their use
AU2023347072A1 (en) *	2022-09-20	2025-01-02	Currus Biologics Pty Ltd	Bispecific polypeptides and uses thereof
TW202500587A (zh) *	2023-02-16	2025-01-01	法商賽諾菲公司	Cd40結合蛋白

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
PT970126E (pt)	1997-04-14	2001-10-30	Micromet Ag	Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
EP1135498B1 (en)	1998-11-18	2008-01-23	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
US6946129B1 (en) *	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
EP1975182A1 (en)	2000-02-01	2008-10-01	PanGenetics B.V.	CD40-binding APC-activating molecules
US20030059427A1 (en) *	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL1707627T3 (pl) *	2003-12-25	2013-04-30	Kyowa Hakko Kirin Co Ltd	Mutant antagonistycznego przeciwciała anty-CD40
WO2005123780A2 (en)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1781328A4 (en) *	2004-07-10	2009-06-03	Alexion Pharma Inc	METHOD FOR DETECTING SPECIFIC ANTIBODIES TO CANCER CELLS AND ANTIBODIES SOUND
CA2587766A1 (en)	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
US20090074711A1 (en) *	2006-09-07	2009-03-19	University Of Southhampton	Human therapies using chimeric agonistic anti-human cd40 antibody
EP2066349B1 (en) *	2006-09-08	2012-03-28	MedImmune, LLC	Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
EP2205631B1 (en) *	2007-10-05	2016-11-23	Genentech, Inc.	Methods and compositions for diagnosis and treatment of amyloidosis
EP2552965A2 (en) *	2010-03-31	2013-02-06	Boehringer Ingelheim International GmbH	Anti-cd40 antibodies
US8778345B2 (en)	2011-04-29	2014-07-15	Apexigen, Inc.	Anti-CD40 antibodies
GB201115280D0 (en) *	2011-09-05	2011-10-19	Alligator Bioscience Ab	Antibodies, uses and methods
AU2013306700B2 (en) *	2012-08-24	2019-05-02	Chugai Seiyaku Kabushiki Kaisha	FcgammaRIIb-specific Fc region variant
WO2014070934A1 (en) *	2012-10-30	2014-05-08	Apexigen, Inc.	Anti-cd40 antibodies and methods of use
JP6449229B2 (ja) *	2013-03-15	2019-01-09	アッヴィ・バイオセラピューティクス・インコーポレイテッド	Ｆｃ変異体
GB201322583D0 (en) *	2013-12-19	2014-02-05	Alligator Bioscience Ab	Antibodies
SG10201913099YA (en)	2014-10-29	2020-02-27	Seattle Genetics Inc	Dosage and administration of non-fucosylated anti-cd40 antibodies
PE20180193A1 (es) *	2015-05-29	2018-01-26	Abbvie Inc	Anticuerpos anti-cd40 y sus usos
BR112018074453A2 (pt) *	2016-05-27	2019-03-19	Abbvie Biotherapeutics Inc.	proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
SI3464361T1 (sl) *	2016-05-27	2022-01-31	Abbvie Biotherapeutics Inc.	Protitelesa proti CD40 in njihove uporabe

2017
- 2017-05-26 SI SI201731001T patent/SI3464361T1/sl unknown
- 2017-05-26 RS RS20211552A patent/RS62726B1/sr unknown
- 2017-05-26 KR KR1020187037322A patent/KR102366355B1/ko not_active Expired - Fee Related
- 2017-05-26 NZ NZ748644A patent/NZ748644A/en not_active IP Right Cessation
- 2017-05-26 BR BR112018074468-9A patent/BR112018074468A2/pt not_active IP Right Cessation
- 2017-05-26 MY MYPI2018002113A patent/MY195442A/en unknown
- 2017-05-26 SG SG11201810522UA patent/SG11201810522UA/en unknown
- 2017-05-26 CN CN201780046023.8A patent/CN109476750B/zh active Active
- 2017-05-26 WO PCT/US2017/034681 patent/WO2017205742A1/en not_active Ceased
- 2017-05-26 CR CR20180605A patent/CR20180605A/es unknown
- 2017-05-26 TW TW106117521A patent/TWI761348B/zh not_active IP Right Cessation
- 2017-05-26 CA CA3025347A patent/CA3025347A1/en active Pending
- 2017-05-26 JP JP2018561225A patent/JP2019523221A/ja not_active Withdrawn
- 2017-05-26 SG SG10201914132RA patent/SG10201914132RA/en unknown
- 2017-05-26 LT LTEPPCT/US2017/034681T patent/LT3464361T/lt unknown
- 2017-05-26 PL PL17728411T patent/PL3464361T3/pl unknown
- 2017-05-26 PT PT177284114T patent/PT3464361T/pt unknown
- 2017-05-26 SM SM20210721T patent/SMT202100721T1/it unknown
- 2017-05-26 KR KR1020227005372A patent/KR20220028143A/ko not_active Withdrawn
- 2017-05-26 RU RU2018146533A patent/RU2752049C2/ru active
- 2017-05-26 PE PE2018003115A patent/PE20190970A1/es unknown
- 2017-05-26 TW TW111109284A patent/TWI814279B/zh not_active IP Right Cessation
- 2017-05-26 US US15/606,227 patent/US10519243B2/en active Active
- 2017-05-26 AU AU2017271602A patent/AU2017271602A1/en not_active Abandoned
- 2017-05-26 HU HUE17728411A patent/HUE056670T2/hu unknown
- 2017-05-26 HR HRP20211882TT patent/HRP20211882T1/hr unknown
- 2017-05-26 EP EP17728411.4A patent/EP3464361B1/en active Active
- 2017-05-26 UA UAA201812784A patent/UA123111C2/uk unknown
- 2017-05-26 ES ES17728411T patent/ES2901722T3/es active Active
- 2017-05-26 AR ARP170101447A patent/AR108611A1/es not_active Application Discontinuation
- 2017-05-26 IL IL263223A patent/IL263223B2/en unknown
- 2017-05-26 EP EP21200482.4A patent/EP3995511A1/en not_active Withdrawn
- 2017-05-26 MX MX2018014630A patent/MX393455B/es unknown
2018
- 2018-02-21 US US15/901,560 patent/US10023645B1/en active Active
- 2018-07-16 US US16/036,691 patent/US10400041B2/en active Active
- 2018-11-22 PH PH12018502456A patent/PH12018502456A1/en unknown
- 2018-11-26 DO DO2018000258A patent/DOP2018000258A/es unknown
- 2018-11-26 CL CL2018003366A patent/CL2018003366A1/es unknown
- 2018-11-26 CO CONC2018/0012699A patent/CO2018012699A2/es unknown
- 2018-12-21 EC ECSENADI201894829A patent/ECSP18094829A/es unknown
2019
- 2019-09-03 US US16/559,504 patent/US10844131B2/en active Active
- 2019-10-21 US US16/659,209 patent/US10597460B2/en active Active
2020
- 2020-10-16 US US17/073,150 patent/US20210024642A1/en not_active Abandoned
2021
- 2021-05-21 US US17/327,264 patent/US20210277137A1/en not_active Abandoned
- 2021-12-03 CY CY20211101058T patent/CY1124806T1/el unknown
- 2021-12-30 US US17/566,149 patent/US20220119542A1/en not_active Abandoned
2022
- 2022-01-24 AR ARP220100135A patent/AR124692A2/es not_active Application Discontinuation
- 2022-02-18 JP JP2022023569A patent/JP7331179B2/ja active Active

Also Published As

Publication number	Publication date
IL263223B (en)	2022-11-01
US20190071509A1 (en)	2019-03-07
RS62726B1 (sr)	2022-01-31
JP7331179B2 (ja)	2023-08-22
SMT202100721T1 (it)	2022-01-10
EP3995511A1 (en)	2022-05-11
DOP2018000258A (es)	2019-02-15
TW202229356A (zh)	2022-08-01
AR108611A1 (es)	2018-09-05
TW201806971A (zh)	2018-03-01
CL2018003366A1 (es)	2019-03-15
CN109476750B (zh)	2022-02-01
NZ748644A (en)	2023-05-26
LT3464361T (lt)	2022-01-10
US10519243B2 (en)	2019-12-31
US10023645B1 (en)	2018-07-17
WO2017205742A1 (en)	2017-11-30
BR112018074468A2 (pt)	2019-03-06
HUE056670T2 (hu)	2022-02-28
KR20190014524A (ko)	2019-02-12
CR20180605A (es)	2020-01-13
PH12018502456A1 (en)	2019-10-21
RU2752049C2 (ru)	2021-07-22
PT3464361T (pt)	2021-12-27
JP2022068294A (ja)	2022-05-09
ES2901722T3 (es)	2022-03-23
US10400041B2 (en)	2019-09-03
KR20220028143A (ko)	2022-03-08
US10844131B2 (en)	2020-11-24
US20180186889A1 (en)	2018-07-05
US10597460B2 (en)	2020-03-24
AU2017271602A1 (en)	2018-12-13
AR124692A2 (es)	2023-04-26
TWI814279B (zh)	2023-09-01
CY1124806T1 (el)	2022-11-25
SG10201914132RA (en)	2020-03-30
PE20190970A1 (es)	2019-07-09
US20210277137A1 (en)	2021-09-09
EP3464361B1 (en)	2021-11-10
IL263223B2 (en)	2023-03-01
UA123111C2 (uk)	2021-02-17
HRP20211882T1 (hr)	2022-03-04
CO2018012699A2 (es)	2019-08-20
JP2019523221A (ja)	2019-08-22
SG11201810522UA (en)	2018-12-28
US20210024642A1 (en)	2021-01-28
MX393455B (es)	2025-03-24
US20220119542A1 (en)	2022-04-21
TWI761348B (zh)	2022-04-21
US20170342159A1 (en)	2017-11-30
MY195442A (en)	2023-01-21
RU2018146533A (ru)	2020-06-29
PL3464361T3 (pl)	2022-01-31
US20200040090A1 (en)	2020-02-06
EP3464361A1 (en)	2019-04-10
KR102366355B1 (ko)	2022-02-24
CA3025347A1 (en)	2017-11-30
CN109476750A (zh)	2019-03-15
US20200010558A1 (en)	2020-01-09
MX2018014630A (es)	2019-06-10
ECSP18094829A (es)	2019-03-29
RU2018146533A3 (sl)	2020-06-29
IL263223A (en)	2018-12-31

Publication	Publication Date	Title
IL283321A (en)	2021-07-29	Antibodies against muc16 and their uses
IL263223A (en)	2018-12-31	Antibodies against cd40 and their uses
IL255961B (en)	2022-02-01	Anti-cd40 antibodies and uses thereof
ZA201902265B (en)	2021-10-27	Anti-pd-1 antibodies and their uses
IL266738A (en)	2019-07-31	Novel antibodies and their uses
IL258284A (en)	2018-05-31	Anti-Lag 3 antibodies and their uses
ZA201800536B (en)	2019-07-31	Il-8-binding antibodies and uses thereof
IL257263A (en)	2018-03-29	Antibodies against angptl8 and their use
HUE056769T2 (hu)	2022-03-28	Humanizált anti-CD40 antitestek és felhasználásuk
SG10202109691UA (en)	2021-10-28	Anti-pacap antibodies and uses thereof
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
IL254954B (en)	2021-10-31	Anti-pacap antibodies and their uses
PL3292154T3 (pl)	2022-04-19	Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
IL266082A (en)	2019-06-30	Anti-chikv antibodies and their use
IL266049A (en)	2019-06-30	Antibodies against o1 and their uses
IL264417A (en)	2019-02-28	Anti-o2 antibodies and their uses
HK40006958A (en)	2020-05-29	Anti-cd40 antibodies and their uses